Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience
Clinical Neuropharmacology, 2017
1Movement Disorders Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, TelAviv; 2Sackler School of Medicine, TelAviv University, TelAviv; 3Tikun Olam, Research Department, Tel Aviv; 4School of Public Health, Epidemiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv; 5OneWorld Cannabis Ltd, Petah-Tikva; 6Movement Disorders Center, Rabin Medical Center, Petah-Tikva; and 7Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Retrospective cohort study tested 47 Parkinson’s disease (PD) patients and the effect of cannabis on them. Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects.
STUDY POPULATION: 47 patients with Parkinson’s Disease
STRAIN: About half of the patients in the study received the company’s products regularly.
Most of the patients (82.2%) reported that medical cannabis improved their overall symptoms.
The treatment led to a reduction in complaints of falling (from 22/47 [46.8%] to 6/18 [33.3%]).
Reduced general stiffness of the muscles and tremor were reported by 32/44 and 30/41 individuals (72.7% and 73.2%, respectively).
Pain reduction was reported by 35/43 individuals (81.4%).
Three quarters of the subjects (35/46, 76.1%) reported an improvement in mood.
Most of the patients reported an improvement in sleep quality (33/46, 71.7%).